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Abstract
Background: Little is known about the dynamics of colonizing Enterococcus faecium clones during hospitalization,
invasive infection and after discharge.
Methods: In a prospective observational study we compared intestinal E. faecium colonization in three patient
cohorts: 1) Patients from the Hematology Unit at the University Hospital Basel (UHBS), Switzerland, were
investigated by weekly rectal swabs (RS) during hospitalization (group 1a, n = 33) and monthly after discharge
(group 1b, n = 21). 2) Patients from the Intensive Care Unit (ICU) at the University Medical Center Utrecht, the
Netherlands (group 2, n = 25) were swabbed weekly. 3) Patients with invasive E. faecium infection at UHBS were
swabbed at the time of infection (group 3, n = 22). From each RS five colonies with typical E. faecium morphology
were picked. Species identification was confirmed by PCR and ampicillin-resistant E. faecium (ARE) isolates were
typed using Multiple Locus Variable Number Tandem Repeat Analysis (MLVA). The Simpson’s Index of Diversity
(SID) was calculated.
Results: Out of 558 ARE isolates from 354 RS, MT159 was the most prevalent clone (54%, 100%, 52% and 83% of
ARE in groups 1a, 1b, 2 and 3, respectively). Among hematological inpatients 13 (40%) had ARE. During
hospitalization, the SID of MLVA-typed ARE decreased from 0.745 [95%CI 0.657-0.833] in week 1 to 0.513 [95%CI
0.388-0.637] in week 3. After discharge the only detected ARE was MT159 in 3 patients. In the ICU (group 2) almost
all patients (84%) were colonized with ARE. The SID increased significantly from 0.373 [95%CI 0.175-0.572] at week
1 to a maximum of 0.808 [95%CI 0.768-0.849] at week 3 due to acquisition of multiple ARE clones. All 16 patients
with invasive ARE were colonized with the same MLVA clone (p < 0.001).
Conclusions: In hospitalized high-risk patients MT159 is the most frequent colonizer and cause of invasive E.
faecium infections. During hospitalization, ASE are quickly replaced by ARE. Diversity of ARE increases on units with
possible cross-transmission such as ICUs. After hospitalization ARE are lost with the exception of MT159. In invasive
infections, the invasive clone is the predominant gut colonizer.
Background
Over the last decades Enterococcus faecium has emerged
as an important nosocomial pathogen [1-3]. Molecular
epidemiological studies using Multilocus Sequence Typ-
ing (MLST) [4] identified a genetic subpopulation of E.
faecium clones that causes the majority of nosocomial
infections and hospital outbreaks. It is characterized by
resistance to various antibiotics, such as ampicillin
(ARE), quinolones and vancomycin (VRE) [5] and acqui-
sition of putative virulence genes [3,6-8]. This subpopu-
lation is distinct from endogenous, genetically diverse
and mostly ampicillin-susceptible E. faecium (ASE) colo-
nizing the gastrointestinal tract of healthy individuals
[9-12].
Prerequisite for infection is intestinal colonization
[13]. Whether hospital-associated ARE originate from
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cium clones under antibiotic selection pressure or
whether ARE are acquired in the hospital by transmis-
sion from a colonized environment (or other patients) is
not clear [14], although the latter possibility has been
strongly suggested [15,16].
In a prospective observational study we analyzed the
within-patient dynamics and diversity of ARE clones
colonizing high-risk patients on consecutive occasions
during hospitalization and after discharge. Furthermore,
from patients with an invasive ARE infection, genetic
relatedness between the invasive and colonizing ARE
was determined.
Methods
Study population
Three patients groups from different epidemiological
settings were studied prospectively:
Group 1: All patients ≥ 18 years hospitalized
between September 1
st and November 30
th 2009 on a
13-bed hematology ward (for myeloablative che-
motherapy or hematopoietic stem cell transplantation
(HSCT)) of the University Hospital Basel (UHBS), a
600-bed tertiary care center in Switzerland were
included (group 1a). Rectal swabs (RS) were obtained
once weekly. Patients were treated in single rooms,
supplied with laminar airflow, positive pressure and
protective care. No antibiotic prophylaxis was admi-
nistered besides trimethoprim/sulfamethoxazole for
Pneumocystis jirovecii. In the 6 months after discharge,
RS were obtained monthly during outpatient consulta-
tions (group 1b).
Group 2: All patients ≥ 18 years hospitalized between
October 20
th and December 31
st 2010 on a 30-bed
Intensive Care Unit (ICU) of the University Medical
Center Utrecht (UMCU), a 1042-bed tertiary care hospi-
tal in the Netherlands, had weekly RS. All patients
received selective oropharyngeal decontamination (SOD)
throughout ICU stay consisting of a mouth paste with
non-absorbable anti-infectives (colistine, tobramycin and
amphotericin B) [17]. Patients in groups 1 and 2 were
eligible for analysis if at least three consecutive swabs
were available.
Group 3: All patients ≥ 18 years with documented
invasive infection with E. faecium hospitalized on any
ward of the University Hospital Basel were included
from September 1
st 2009 until May 31
st 2010. A single
RS was obtained as soon as an invasive E. faecium infec-
tion was microbiologically confirmed.
Microbiologic analysis
RS were obtained using a sterile cotton swab mois-
tened with sterile 0.9% NaCl and immediately sent to
the microbiological laboratory in a transport medium.
RS were inoculated for 48 hours in Enterococcal
Enrichment Broth (Becton-Dickinson, Cockeysville,
MD, USA) supplemented with 75 mg/L aztreonam for
suppression of Gram-negative bacteria. If positive
(black coloration of the broth), 100 μl of well-mixed
suspension were plated on Slanetz-Bartley Agar (Oxoid
Ltd Basingstoke Hampshire, England) for 48 hours.
Five colonies with a morphology typical for E. faecium
were picked at random. If different morphotypes were
present, five colonies from each morphotype were
picked and grown on blood agar plates (BD trypticase
soy agar with 5% sheep blood, Becton-Dickinson, Hei-
delberg, Germany). Bacterial lysates were prepared as
described elsewhere [18]. An E. faecium species-speci-
fic PCR based on the ddl gene was performed to con-
firm species identity [19].
For invasive isolates, minimal inhibitory concentra-
tions (MICs) for ampicillin and vancomycin were deter-
mined using a semiautomated microbroth dilution
system (Micronaut, Merlin, Bornheim-Hersel, Germany).
Isolates from RS were plated onto Enterococcosel Agar
(Becton-Dickinson, Sparks, MD, USA) containing 60
mg/L aztreonam and 16 mg/L ampicillin to determine
ampicillin susceptibility. Growth (indicating ampicillin
resistance) was determined after 48 hours of incubation
in aerobic conditions. Susceptibility was interpreted
according breakpoints established by the Clinical and
Laboratory Standards Institute (CLSI) for ampicillin
(susceptible ≤ 8 mg/L, resistant ≥ 16 mg/L) and for van-
comycin (susceptible ≤ 4 mg/L, intermediate 8-16 mg/L
and resistant ≥ 32 mg/L) [20].
MLVA was performed on all ARE isolates from RS
and invasive infections as described previously [21]. For
isolates with incomplete MLVA-profiles, the Expand
Long Template PCR system (Roche Diagnostics, Man-
nheim, Germany) was used on purified chromosomal
DNA. MLVA types were assigned using the web-based
database available at http://www.umcutrecht.nl/subsite/
MLVA.
Definitions
Duration of colonization by a clone was defined by the
time between the first and the last detection. According
to CDC-guidelines [22] two negative swabs were allowed
in between. If three or more swabs were negative
between two positive swabs, the second positive one was
considered to represent a new acquisition. End of colo-
nization was defined as the last positive swab, regardless
of how many negative swabs were documented there-
after. If growth was documented only in a single swab,
colonization time was defined arbitrarily as three days.
Duration of antibiotic treatment was calculated in days
with administration of an antibiotic regardless of class
or changes in antibiotics.
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Longitudinal data was analyzed per hospitalization and
per patient for outpatient-follow-up. In order to quantify
the diversity of the different MLVA types of ARE, the
Simpson’s index of diversity (SID, Ridom EpiCompare
®)
[23,24] was used. The SID takes into account the num-
ber of different MLVA types in relation to the total
number of isolates and was calculated for weeks 1-4 of
hospitalization in groups 1a and 2. For group 1b SID
was calculated for ARE isolates for intervals of 2-3
months. The SID was not calculated for later time
points as the number of ARE isolates were too small (<
15) due to discharge of patients. For differences between
hospitalization and ARE colonization rates, the Fisher’s
exact test was used. For comparison of ASE and ARE
invasive infections the Fisher’s exact test was used for
categorical variables and the Mann Whitney test for
continuous variables. A 2-sided p-value of < 0.05 was
considered to be statistically significant. Analyses were
performed using STATA™ software version 11 for Win-
dows (StataCorp, College Station, TX, USA).
Institutional review board (IRB)
All samples were part of the regular infection control
surveillance program conducted by Hospital Hygiene
and Infection Control. Approval from the local ethical
committee (EKBB Rfe Number 208/09) was obtained.
Results
Patients and rectal swabs (RS)
Baseline characteristics of the 77 included patients are
summarized in Table 1. Thirty-three of 34 patients
admitted to the Hematology ward UHBS had at least 3
RS (group 1) during a total of 43 hospitalizations, of
which 41 (95%) were admitted from home. Eight
patients were already hospitalized at start of the study,
and first swabs were, therefore, obtained after the first
week of admission in these patients. Twenty-one of 27
patients from group 1a, who survived hospitalization,
were included in outpatient follow-up (group 1b). The
remaining 6 patients were lost to follow-up (of whom
one was treated in another centre).
From a total of 184 patients admitted to the ICU
UMCU (group 2), 25 were hospitalized 3 weeks or more
and at least 3 RS could be obtained during 29 hospitali-
zations. In sixteen out of 29 ICU admissions (55%) the
patient was directly transferred from another ward in
the same hospital. From six patients the first RS was
obtained later than the first week after ICU-admission.
At the UHBS 29 invasive infections with E. faecium
were documented in 25 hospitalized patients (including
3 patients from group 1a) during the study period. In 22
patients a RS could be obtained at a median of 6 days
after the first blood culture became positive (Interquar-
tile range (IQR) 5-10).
Overall, 354 RS from 77 patients were analyzed. In
about half of all RS (166 of 354, 47%) 849 E. faecium
isolates were identified. ARE were present in 106 RS
accounting for 558 isolates.
Diversity of ARE
MLVA typing of the 558 ARE isolates yielded 16 differ-
ent MLVA types (MTs) including 6 previously unidenti-
fied MTs. A remarkable predominance of MT159 was
found (30%, 23%, 45% and 61% of all E. faecium isolates
and 54%, 100%, 52% and 83% of all ARE in groups 1a,
1b, 2 and 3, respectively). Other predominant ARE
clones are shown in Table 1. MT159 was present at the
time of first sampling in 7% of hospitalizations in
group1a and in 17% of hospitalizations in group 2. The
acquisition rates of MT159 during hospitalization were
7% and 31% in groups 1a and 2, respectively. During
outpatient follow-up MT159 was acquired in one
patient.
Dynamics of colonizing E. faecium clones
Table 2 shows the distribution of E. faecium in patients
during follow-up: In group 1, in 22 of 33 (67%) patients
E. faecium w a si s o l a t e df r o maR Sa tl e a s to n c e ,1 3
(40%) patients had at least one ARE. In group 2, 23 of
25 (92%) patients had at least one RS positive for E. fae-
cium and in 21 (84%) patients an ARE was detected at
least once. The highest proportion of patients with ASE
only was in group 1b (Table 2). A minority of patients
had one ARE clone only during the follow-up (4, 2 and
12 in groups 1a, 1b and 2, respectively). In 9 patients
from group 2 (36%) only MT159 was documented. In 6
o u to f3 3p a t i e n t sf r o mg r o u p1 ,as w a bc o n t a i n i n ga n
ASE was followed by an ARE positive swab, which was
interpreted as an ASE to ARE replacement. Replacement
of ARE by ASE occurred in only 1 patient from group 1
and 2 patients from group 2.
Table 3 shows the dynamics of ARE clones per hos-
pitalization and outpatient treatment: In group 1a, the
number of E. faecium isolates cultured per week
d e c l i n e df r o m7 4( 3 4A R E ,4 0A S E )i nw e e k1t o3 7
( 2 0A R E ,1 7A S E )i nw e e k4 .T h eS I Do fM L V A - t y p e d
ARE increased slightly but not significantly from
0.745 [95%CI 0.657-0.833] in week 1 to 0.775 [95%CI
0.684-0.866] in week 2 probably due to acquisition of
ARE clones and then dropped significantly to 0.513
[95%CI 0.388-0.637] in week 3 and to zero in week 4
with loss of all ARE except MT159 in this last time
point (Table 3 Figure 1). The decrease in SID was
accompanied by a substantial loss of ASE during the
first 2 weeks of hospitalization. Acquisition of ARE
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lizations, mostly (n = 5) occurring between week 1
and 2.
Colonization with MT159 was detected at the first
swab occasion in three (7%) of 43 hospitalizations
involving three different patients; two of these patients
h a ds u f f e r e df r o ma ni n v a s i v ei n f e c t i o nw i t hE. fae-
cium MT159 during the previous year. In three hospi-
talizations MT159 was acquired during stay at the
hematology; two of these patients had been transferred
to and from an ICU. In all six hospitalizations MT159
colonization persisted until discharge, whereas 7 non-
MT159 ARE clones disappeared before discharge in 5
patients.
Of the 21 patients of group 1b three patients
remained colonized with ARE during the first three
months after hospital discharge. All these ARE were
MT159.
In the ICU (group 2), almost all E. faecium isolates
were ARE. The SID of ARE isolates increased signifi-
cantly from 0.373 [95%CI 0.175-0.572] at week 1 to a
maximum of 0.808 [95%CI 0.768-0.849] at week 3. Dur-
ing week 4 SID decreased slightly to 0.781 [95%CI
0.725-0.837]. ARE were detected in the first swab in
eight (28%) of 29 hospitalizations; five belonged to
MT159; in six admissions the patient was transferred
from another ward to ICU. There were 24 ARE acquisi-
tions (comprising 8 different clones) during 29 ICU
Table 1 Baseline Characteristics
Hematology UHBS ICU UMCU INV UHBS
Group 1a Group 1b Group 2 Group 3
Patients
Screened patients; n 34 33 184 25
Included patients (≥ 3RS); n(%) 33 (97) 21 (64) 25 (14) 22 (88)
a
Age, years; median (IQR) 55 (48-63) 53 (43-59) 55 (44-66) 69 (50-78)
Male sex; n (%) 18 (55) 11 (52) 19 (76) 13 (59)
Hospitalization during the previous year; n (%)
- At the same institution 14 (42) NA 10 (40) 11 (50)
- At another hospital 13 (39) NA NA 4 (18)
Death at end of follow-up, n (%) 6 (18) 12 (36) 10 (40) 7 (32)
Episodes of hospitalization 43 NA 29 22
Duration of hospitalization, days; median (IQR)
- Hematology/ICU 27 (11-40) NA 28 (18-48) NA
- Any ward 33 (19-53) NA 60 (42-78) NA
Referral from another ward in the hospital, n (%) 2 (5) NA 16 (55) NA
Antibiotic treatment, n (%) 34 (79) NA 28 (97) NA
- Duration, days; median (IQR) 25 (15-38) 20 (14-33)
- Antibiotics at admission, n (%) 14 (33) 6 (21)
- Days to start since admission
b, 6 (4-11) 2 (2-4)
median (IQR)
Rectal swabs; n 152 67 113 22
median per hospitalization (IQR) 3 (2-4) 3 (2-3)
c 3 (3-5) 1
swabs containing E. faecium 59 24 62 21
E. faecium isolates; n 287 107 335 120
ARE; n (% of all isolates) 157 (55) 25 (23) 288 (86) 88 (73)
- MT159 85 (30) 25 (23) 151 (45) 73 (61)
- MT1 17 (6) 0 19 (6) 10 (8)
- MT 10 0 0 24 (7) 0
- MT12 10 (3) 0 47 (14) 0
- MT 282 19 (7) 0 0 5 (4)
- other ARE 26 (9)
d 0 47 (14)
e 0
MT159 in first swab, n (%) 3 (7) 3 (14)
f 5 (17) NA
MT159 acquisition during hospitalization, n (%) 3 (7) 1 (5) 9 (31) NA
UHBS University Hospital Basel; UMCU University Medical Center Utrecht; ICU Intensive Care Unit; INV Invasive Infections, NA not applicable; RS rectal swab; ARE
ampicillin-resistant E. faecium; ASE ampicillin-susceptible E. faecium; IQR Interquartile range;
a patients with 1 RS at the time of invasive infection, 3 patients from group 1 are also included in 3;
b in patients not treated with antibiotics at admission;
c
swabs performed during outpatient follow-up;
d 7 different MTs;
e 6 different MTs;
f positive swab at time of discharge in outpatients
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(31%). Most clones were acquired during the first 3
weeks (Figure 1). In only 4 patients (7 hospitalizations)
no ARE were detected. Disappearance of a clone at the
time of discharge occurred for 14 (70%) of 20 non-
MT159-ARE clones in 11 patients and for 4 (29%) of 14
MT159 in 14 patients (p < 0.02).
Antibiotic consumption was high in all hospitalized
patients (Table 1): In group 1a, during 34 hospitaliza-
tions out of 43 (79%) broadspectrum antibiotics were
administered for a median duration of 25 days (IQR 25-
38), which corresponds almost to the whole duration of
hospitalization. In group 2, administration of antibiotics
was even higher (28 out of 29 hospitalizations (97%))
with a median duration of 20 days (IQR 14-33). During
hospitalizations without administration of antibiotics,
acquisition of ARE was low (1 out of 9 hospitalizations
( 1 1 % )i ng r o u p1 aa n d0o u t1h o s p i t a l i z a t i o ni ng r o u p
2). In contrast, during hospitalizations with antibiotic
treatment, acquisition ofA R Ew a sm o r ef r e q u e n t( 1 3
out of 34 hospitalizations (38%) in group 1a and 22 out
of 28 hospitalizations (79%) in group 2).
Invasive Infections with E. faecium
The majority (91%) of 22 invasive isolates was obtained
from a blood culture (Table 4). All 22 isolates were sus-
ceptible to vancomycin, 16 were resistant to ampicillin.
Among invasive infections with ARE 13 of 16 (82%)
were caused by MT159. Other isolates belonged to MT1
(n = 2; 12%), MT282 (n = 1, 6%). An identical MLVA
clone in the RS was present in all 16 patients with inva-
sive ARE infection. Two patients with ARE infection
were co-colonized with ASE. Invasive ARE infections
were mostly monomicrobial (69%), related to central
venous catheter or vascular grafts (75%) and occurred
Table 2 Within-patient distribution of E. faecium isolates
Hematology UHBS ICU
UMCU
Group
1a
Group
1b
Group 2
Patients, n 33 21 25
- with ARE, n (%) 13 (40%) 3 (14%) 21 (84%)
- with only ASE, n (%) 9 (27%) 9 (43%) 2 (8%)
- with no E. faecium, n (%) 11 (33%) 9 (43%) 2 (8%)
Patients with only one MT of ARE
- MT159 1 2 9
- Other ARE 3 0 3
Patients with replacements
a of E.
faecium
- ASE to ARE 6 0 0
- ARE to ASE 1 0 2
- ARE change of MT 2 1 7
UHBS University Hospital Basel; ICU Intensive Care Unit; UMCU University
Medical Center Utrecht; ARE ampicillin-resistant E. faecium; ASE ampicillin-
susceptible E. faecium
a Replacement of an ampicillin-susceptible by an
ampicillin-resistant clone in consecutive swab or vice versa or replacement of
an ARE by a different ARE MT clone
Table 3 Diversity of ARE clones over time
Week 1 Week 2 Week 3 Week 4
Group 1a: Hospitalizations of hematological inpatients UHBS (n = 43)
E. faecium isolates, n 74 67 30 37
ARE, n 34 43 13 20
ASE, n 40 24 17 17
SID of ARE 0.745 0.775 0.513 0
95% Confidence Interval [0.657-0.833] [0.684-0.866] [0.388-0.637] [0.0-0.0]
Month 1 & 2 Month 3 & 4 Month 5 & 6 & 7
Group 1b: Hematological Outpatients UHBS (n = 21)
E. faecium isolates, n 46 31 30
ARE, n 20 5 0
ASE, n 26 26 30
SID of ARE 0 0
95% Confidence Interval [0.0-0.0] [0.0-0.0]
Week 1 Week 2 Week 3 Week 4
Group 2: Hospitalizations of Intensive Care Unit UMCU (n = 29)
E. faecium isolates, n 31 69 76 50
ARE, n 27 69 76 45
ASE, n 40 0 5
SID of ARE 0.373 0.676 0.808 0.781
95% Confidence Interval [0.175-0.572] [0.58-0.772] [0.768-0.849] [0.725-0.837]
UHBS University Hospital Basel; UMCU University Medical Center Utrecht; SID Simpson’s Index of Diversity; ARE ampicillin-resistant E. faecium; ASE ampicillin-
susceptible E. faecium
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Page 5 of 9Figure 1 Dynamics of colonizing E. faecium clones. Bars indicate the proportion of E. faecium isolates among the collected isolates at
different time points; black color indicates MT159 clones, dark grey ampicillin-resistant non-MT159 clones and white color indicates ampicillin-
susceptible non-typed E. faecium isolates. The black line shows the Simpson’s index of diversity for ARE during the first 4 weeks in hospitalized
patients and during months 1 & 2, 3 & 4 and 5, 6 & 7 in hematological outpatients. Confidence intervals are indicated in the text. Numbers of
swabs are shown below the graph. Fluctuation in numbers of swabs is due to missing admission swabs in 8 hospitalizations (in which patients
have been on the ward before start of the study), to discharge of patients at different time points and to lack of 3 swabs during hospitalization.
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tions with MT159 (69%) occurred during or after stay in
ICU. ASE infections were more often polymicrobial
(67%), resulted from cholangitis (83%) and occurred
early (median of 3 hospitalization days). In these
patients, no ARE were found in the RS.
Discussion
In this study we have demonstrated the predominance
of a single clone (MT159) of E. faecium colonizing hos-
pitalized patients and causing invasive infections in two
hospitals in Switzerland and the Netherlands. In hema-
tological patients admitted directly from home ASE car-
riage was rapidly replaced by ARE, mainly MT159. In
these patients ARE carriage disappeared after hospital
discharge with the exception of MT159, which persisted
in three patients. In patients from ICU ARE were abun-
dant already on admission and increased in diversity
during ICU stay.
In the two epidemiological settings examined,
dynamics of ARE were different. In hematological
patients the SID at admission was high (0.745) com-
pared to patients from ICU (0.373). In parallel the
amount of ASE was much higher in hematological
patients. This can partly be explained by differences in
baseline characteristics: Hematology patients are predo-
minantly admitted directly from home and thus have
been transferred from another ward less frequently than
patients from ICU (5% vs 55%, respectively, p < 0.01).
As a result, ARE prevalence, which is typical for hospital
environments, at the time of the first swab tended to be
lower (19% versus 28% respectively, p < 0.05). Differ-
ences in the prevalence of ARE carriage in the commu-
nity cannot be excluded, but seem less probable. In the
Netherlands the proportion of ARE in 650 community-
derived fecal samples was 3% in 2007 [21] and was
unchanged in 2010 despite the increase of ARE in hos-
pitals (J. Top, personal communication).
During hospitalization (week 3) the SID decreased sig-
nificantly in haematological patients due to loss of ARE
other than MT159 and a few acquisitions of MT159. In
contrast, in ICU patients, the SID increased significantly
during the first week of hospitalization due to acquisi-
tion of different ARE clones. Acquisition rates of ARE
during hospitalization were markedly higher in ICU
(83%) than in hematological patients (19%). This could
be related to protective care measures in single rooms
for hematology patients, while ICU patients were, at the
time of the study, treated in 5-bed-rooms, increasing the
chance of cross-transmission. In both study groups,
most acquisitions occurred at week 2 and 3 of hospitali-
zation. As we swabbed only once weekly the exact time
point of acquisition might have been earlier. In both
groups antibiotic consumption was high (group 1a 79%,
group 2 97%). A proper correlation between acquisition
of ARE and antibiotic consumption was unfortunately
not feasible due to low numbers. Thus the increase in
ARE could also correspond to a selection of pre-existing
ARE outnumbering ASE. In this study all patients in
ICU received SOD, an oral antibiotic-containing paste,
which may promote colonization in ARE [25,26]. Addi-
tionally, ARE epidemiology at the UMCU could be char-
acterized as endemic with clonal diversification and
polyclonal expansion since 2000 [27], whereas an
increase in invasive ARE infections in the University
Hospital Basel was observed only after 2004 (data not
shown).
Our findings of a decrease in diversity of E. faecium
isolates at later time points during hospitalization in
hematology patients, is in agreement with a recently
published study: In 8 patients admitted from home to a
neurosurgical ICU in Madrid, Spain, a newly generated
index quantifying daily diversity showed a decrease of E.
faecium diversity with persistence of nosocomial clones
during hospitalization [14]. We used the SID to quantify
diversity based on 5 at random picked E. faecium iso-
lates from weekly rectal swabs. The SID is an estab-
lished measure of biodiversity [24], but is usually used
in larger sample sizes. One could argue that numbers of
isolates - ranging from 17 to 76 per time point - were
too small to adopt such an index. We decided therefore
Table 4 Invasive Infections with E. faecium
ARE n =
16
ASE n =
6
p-
value
Source of microbiological sample
- blood, n (%) 14 (88) 6 (100) 0.519
- abscess-drainage, n (%) 2 (12) 0
Polymicrobial infection, n (%) 5 (31) 4 (67) 0.155
Underlying disease, n (%)
Hematological malignancy 5 (31) 1 (17)
Hepatobiliary disease 2 (13) 5 (83)
Intestinal disease (M. Crohn) 1 (6) 0 0.031
Vascular graft 3 (19) 0
Other
a 5 (31) 0
Clinical presentation, n (%)
CVC-related infection 5 (31) 0
CVC colonization 4 (25) 1 (17)
Infection of vascular prosthesis 3 (19) 0 0.046
Cholangitis 2 (13) 5 (83)
Other
b 2 (13) 0
Days since admission, median (IQR) 20 (10-29) 3 (1-11) 0.089
Hospitalization on Intensive Care, n
(%)
9 (56) 2 (33) 0.318
Death, n (%) 6 (38) 1 (17) 0.35
CVC central venous line; IQR interquartile range,
a chronic obstructive
pulmonary disease (2), intravenous drug use (1), lung cancer (1),
spondylodiscitis (1);
b intraabdominal abscess/peritonitis (1), unknown (1)
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least 15 available isolates, which was the case for the
first four weeks of hospitalization.
During follow-up, 55% of patients with E. faecium
colonization carried more than 1 ARE clone. During 17
hospitalizations, 25 ARE clones were no longer detected
at the last swab before discharge (7 in group 1a and 18
in group 2). This could be due to real acquisition and
subsequent loss of clones, or to the low sensitivity of
the RS culture method. The sensitivity of directly inocu-
lating swabs on selective agar was estimated between
58-80% for VRE [28,29] with a detection limit of 4 log10
colony-forming units of VRE/g feces [29]. To enhance
sensitivity, we used an enrichment step before plating
[30]. The ‘loss’ of ARE after discharge might represent a
reduced selection pressure with bacterial loads decreas-
ing to levels below detection limits.
MT159 persisted in patients from both hospitals
(100% in group 1a, 71% in group 2). After discharge
(group 1b) MT159 was found in 3 patients and persisted
throughout follow-up in 2 patients. Higher persistence
of ARE relative to ASE clones has been reported [14].
Since 2004, MT159 isolates, represented by ST78, has
emerged as an epidemic E. faecium clone causing inva-
sive infections and hospital outbreaks in many hospitals
worldwide [15,21,31,32]. The reason for its particular
success in spread and infection is not understood.
Although acquisition of multiple antibiotic resistance
genes and genes that enhance colonization and infection
capacities might contribute, such acquisitions appear
not unique for MT159 [3,33]. Possibly, the high propen-
sity to persist contributes to the ecological success of
this clone.
MLVA has been proposed as a tool to study genetic
relatedness in E. faecium with comparable discrimina-
tory index compared to MLST [18], although other stu-
dies indicated that MLVA might be less discriminatory
than PFGE and MLST [32,34]. In a study from 2008 we
showed that PFGE and MLVA produced highly concor-
dant results when assigning genotypes to nosocomial E.
faecium isolates [35]. Because MLVA is faster than
PFGE and MLST, which was an important criterion
when analyzing such a high amount of isolates, we have
selected MLVA for this study.
At the patient level, there was 100% concordance in E.
faecium MLVA-types among ARE isolates causing inva-
sive infections and isolates from rectal swabs. Most
invasive ASE infections were polymicrobial (67%) and of
hepatobiliary origin (83%) in patients admitted from
home in contrast to ARE infections, which were predo-
minantly monomicrobial (69%) and associated with a
haematological malignancy (31%), ICU stay (56%) and
presence of vascular foreign bodies (75%). This under-
scores, the concept that nosocomial E. faecium
infections are predominantly caused by ARE acquired
during hospitalization and that endogenous ASE only
sporadically cause invasive infections.
Conclusion
In hospitalized high-risk patients MT159 is the most
frequent colonizer and cause of invasive E. faecium
infections. During hospitalization, ASE are quickly
replaced by ARE. Diversity of ARE increases on units
with possible cross-transmission such as ICUs. After
hospitalization ARE are no longer detectable with the
exception of MT159 which was able to persist.
In patients with invasive infections, the invasive clone
is also the predominant colonizer in the gut. Invasive
ARE infections were mostly monomicrobial, related to
vascular devices and appear mostly in patients with long
hospitalizations
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